Genfit Buys Versantis to Rebuild its Liver Disease Portfolio
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 9 (Table of Contents)
Published: 21 Sep-2022
DOI: 10.3833/pdr.v2022.i9.2723 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to bolster its portfolio of liver disease drugs, Genfit has entered into an agreement to acquire Versantis for up to CHF 105 M (US$108...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS